Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?

Francesca AmiciChristian CiarloJenine AbumusallamMadeline KravitzAngel-Rose WeberHanna MeisterZhao Li

Published in: Journal of basic and clinical physiology and pharmacology (2024)

Empagliflozin, liraglutide or combination of these two have cardioprotective effect regardless of diabetes. Cardioprotective effects of SGLT2 inhibitor and GLP-1R agonist is additive and synergistic.

Keyphrases

type diabetes
cardiovascular disease
endothelial cells
cancer therapy
induced apoptosis
metabolic syndrome
adipose tissue
signaling pathway
weight loss